In a move signaling growing confidence in artificial intelligence’s role in medical imaging, Swedish health technology company Sectra has completed its acquisition of Oxipit, a Lithuania-based developer of autonomous AI solutions for radiology. The transaction, finalized in early April 2026, integrates Oxipit’s ChestLink and ChestEye platforms into Sectra’s enterprise imaging portfolio, aiming to expand access to AI-driven diagnostic support across hospitals and clinics worldwide.
Oxipit’s technology, which received CE marking in 2023 and FDA 510(k) clearance in late 2025, is designed to autonomously analyze chest X-rays and flag normal studies with high confidence, allowing radiologists to focus on complex cases. Sectra, which provides imaging IT infrastructure to over 1,800 healthcare facilities globally, said the acquisition accelerates its strategy to embed trustworthy AI directly into clinical workflows without requiring separate systems or disruptive integrations.
The deal reflects broader industry momentum toward AI-assisted radiology, particularly in regions facing workforce shortages. According to the World Health Organization, low- and middle-income countries face a deficit of more than 4 million health workers, including medical imaging specialists. AI tools that can safely triage routine imaging are increasingly seen as a way to stretch limited expertise while maintaining diagnostic quality.
Industry analysts note that autonomous AI in radiology remains a carefully regulated space. While the U.S. Food and Drug Administration has cleared several AI tools for detecting abnormalities in chest X-rays, few have received authorization for fully autonomous operation — meaning the AI can both analyze and report findings without human oversight. Oxipit’s ChestLink is among the few systems globally to achieve this status, having been validated in multi-center studies showing sensitivity and specificity comparable to senior radiologists for detecting normal chest radiographs.
Sectra’s CEO, Torbjörn Kronander, stated in a press release that the acquisition aligns with the company’s long-term vision of “making advanced diagnostics accessible, efficient, and safe.” He emphasized that Oxipit’s technology has been rigorously tested in real-world settings, including pilot programs in Germany and the UK, where it reduced radiologists’ workload by up to 40% on chest X-ray queues without increasing missed findings.
The financial terms of the acquisition were not disclosed. However, Sectra confirmed that Oxipit’s team of 22 engineers and clinical researchers will remain in Vilnius and join Sectra’s growing AI innovation hub. The company said it plans to expand Oxipit’s AI portfolio beyond chest imaging to include other modalities, such as musculoskeletal and pediatric radiology, over the next 24 months.
Experts caution that while AI holds promise, its deployment must be accompanied by robust monitoring and accountability frameworks. The European Union’s AI Act, which came into force in August 2024, classifies most medical AI systems as high-risk, requiring conformity assessments, transparency obligations, and post-market surveillance. Sectra said it will ensure Oxipit’s products remain fully compliant with these regulations as they scale globally.
For healthcare providers, the integration could indicate faster reporting times and reduced burnout among radiology staff, particularly in high-volume settings like emergency departments and tuberculosis screening programs. In countries with high TB burden, automated chest X-ray analysis has shown potential to accelerate case detection, supporting WHO’s End TB Strategy goals.
As AI continues to evolve from decision support to autonomous operation, stakeholders stress the importance of clinician involvement in design, validation, and oversight. Sectra said it will maintain Oxipit’s existing clinical advisory board, which includes radiologists from leading academic hospitals in Scandinavia and the Baltics, to guide future development.
The acquisition marks Sectra’s second major AI-focused purchase in less than two years, following its 2024 acquisition of a Danish AI analytics startup specializing in prostate cancer imaging. Together, these moves position the company as a growing force in the convergence of medical imaging, enterprise IT, and intelligent automation.
Healthcare systems interested in evaluating Oxipit’s technology within Sectra’s enterprise imaging platform can request demonstrations through Sectra’s official website. Updates on regulatory submissions, clinical validation studies, and product roadmaps are typically shared via Sectra’s investor relations portal and press releases.
Stay informed about developments in medical imaging technology and AI in healthcare by following World Today Journal’s Health section. Share your thoughts on how AI is changing radiology in the comments below, and aid spread accurate information by sharing this article with colleagues, and networks.